Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats

Neuropsychopharmacology

Volumn 33, Issue 12, 2008, Pages 2922-2933

  Wallingford, Nicholas M ^a   Sinnayah, Puspha ^a   Bymaster, Frank P ^b   Gadde, Kishore M ^c   Krishnan, Ranga K ^c   McKinney, Anthony A ^b   Landbloom, Ronald P ^b   Tollefson, Gary D ^b   Cowley, Michael A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Orexigen Therapeutics   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; c Fos; Diabetes; Obesity; Orexin; Therapy

Indexed keywords

GLUCOSE; OLANZAPINE; OREXIN; PROTEIN C FOS; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HYPERPHAGIA; HYPOTHALAMUS; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

ANIMALS; ANTICONVULSANTS; APPETITE REGULATION; BENZODIAZEPINES; BIOLOGICAL MARKERS; BODY WEIGHT; DIABETES MELLITUS; FEMALE; HYPERGLYCEMIA; HYPERPHAGIA; HYPOTHALAMIC AREA, LATERAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOXAZOLES; NEURONS; NEUROPEPTIDES; NUCLEUS ACCUMBENS; OBESITY; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 53949119583     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.9     Document Type: Article

References (74)

1. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B et al (2006). Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14: 36-51.
2. Arjona AA, Zhang SX, Adamson B, Wurtman RJ (2004). An animal model of antipsychotic-induced weight gain. Behav Brain Res 152: 121-127.
3. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002). Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35: 205-219.
4. Baulac M, Leppik IE (2007). Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 75: 75-83.
5. Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'Italien GJ, Stockdale W et al (2006). Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 40: 626-632.
6. Brown RR, Estoup MW (2005). Comparison of the metabolic effects observed in patients treated with ziprasidone vs olanzapine. Int Clin Psychopharmacol 20: 105-112.
7. Cluderay JE, Harrison DC, Hervieu GJ (2002). Protein distribution of the orexin-2 receptor in the rat central nervous system. Regul Pept 104: 131-144.
8. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S et al (2006). Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 186: 561-571.
9. Conley RR, Kelly DL (2005). Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 42: 51-60.
10. Cooper GD, Harrold JA, Halford JC, Goudie AJ (2007). Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32: 428-436.
11. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005). A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181: 80-89.
12. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005). Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29: 607-614.
13. Cvetkovic V, Brischoux F, Jacquemard C, Fellmann D, Griffond B, Risold PY (2004). Characterization of subpopulations of neurons producing melanin-concentrating hormone in the rat ventral diencephalon. J Neurochem 91: 911-919.
14. Czapinski P, Blaszczyk B, Czuczwar SJ (2005). Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5: 3-14.
15. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A et al (2003). Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64: 1436-1439.
16. eder-Ischia U, Ebenbichler C, Fleischhacker WW (2005). Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essent Psychopharmacol 6: 112-117.
17. Elman I, Borsook D, Lukas SE (2006). Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31: 2091-2120.
18. Enriori PJ, Evans AE, Sinnayah P, Jobst EE, Tonelli-Lemos L, Billes SK et al (2007). Diet-induced obesity causes severe but reversible leptin resistance in arcuate melanocortin neurons. Cell Metab 5: 181-194.
19. Ettinger AB, Argoff CE (2007). Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 4: 75-83.
20. Fadel J, Bubser M, Deutch AY (2002). Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22: 6742-6746.
21. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE et al (2001). Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatry Res 101: 277-288.
22. Gadde KM, Franciscy DM, Wagner II HR, Krishnan KR (2003). Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 289: 1820-1825.
23. Goudie AJ, Cooper GD, Halford JC (2005). Antipsychotic-induced weight gain. Diabetes Obes Metab 7: 478-487.
24. Goudie AJ, Smith JA, Halford JC (2002). Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16: 291-296.
25. Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB (2005). Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 162: 118-123.
26. Gustafson B, Jack MM, Cushman SW, Smith U (2003). Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha - evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308: 933-939.
27. Harris GC, Aston-Jones G (2006). Arousal and reward: a dichotomy in orexin function. Trends Neurosci 29: 571-577.
28. Harris GC, Wimmer M, Aston-Jones G (2005). A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437: 556-559.
29. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62: 19-28.
30. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA (2001). Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 103: 777-797.
31. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007). Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32: 289-297.
32. Ichikawa J, Chung YC, Dai J, Meltzer HY (2005). Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release. Brain Res 1052: 56-62.
33. Ichikawa J, Meltzer HY (1999). Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur J Pharmacol 380: R1-R3.
34. Kalinichev M, Rourke C, Jones DN (2006). Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone vs olanzapine. Behav Pharmacol 17: 289-292.
35. Kalra SP, Kalra PS (2004). Overlapping and interactive pathways regulating appetite and craving. J Addict Dis 23: 5-21.
36. Kandov Y, Israel Y, Kest A, Dostova I, Verasammy J, Bernal SY et al (2006). GABA receptor subtype antagonists in the nucleus accumbens shell and ventral tegmental area differentially alter feeding responses induced by deprivation, glucoprivation and lipoprivation in rats. Brain Res 1082: 86-97.
37. Kelley AE, Baldo BA, Pratt WE, Will MJ (2005). Corticostriatal- hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 86: 773-795.
38. Kuo DY (2002). Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 9: 126-132.
39. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K (2005). Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 7: 360-369.
40. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
41. Maldonado-Irizarry CS, Swanson CJ, Kelley AE (1995). Glutamate receptors in the nucleus accumbens shell control feeding behavior via the lateral hypothalamus. J Neurosci 15: 6779-6788.
42. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA et al (2006). Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 67: 1897-1906.
43. Melkersson KI, Hulting AL (2001). Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology (Berl) 154: 205-212.
44. Minet-Ringuet J, Even PC, Lacroix M, Tome D, de Beaurepaire R (2006). A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 187: 447-454.
45. Modirrousta M, Mainville L, Jones BE (2005). Orexin and MCH neurons express c-Fos differently after sleep deprivation vs recovery and bear different adrenergic receptors. Eur J Neurosci 21: 2807-2816.
46. Muoio DM, Newgard CB (2006). Obesity-related derangements in metabolic regulation. Annu Rev Biochem 75: 367-401.
47. Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1): 1-93.
48. Newcomer JW, Nasrallah HA, Loebel AD (2004). The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24: S1-S6.
49. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K et al (1995). Effects of zonisamide on dopaminergic system. Epilepsy Res 22: 193-205.
50. Preti A (2002). Orexins (hypocretins): their role in appetite and arousal. Curr Opin Investig Drugs 3: 1199-1206.
51. Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD (2007). Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32: 284-288.
52. Rettenbacher MA, Hummer M, Hofer A, Baumgartner S, Ebenbichler C, Edlinger M et al (2007). Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 21: 400-404.
53. Ritsner MS, Gibel A (2006). The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: a 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry 30: 1442-1452.
54. Robertson GS, Fibiger HC (1996). Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 14: 105-110.
55. Sakurai T (2003). Orexin: a link between energy homeostasis and adaptive behaviour. Curr Opin Clin Nutr Metab Care 6: 353-360.
56. Schwartz MW, Porte Jr D (2005). Diabetes, obesity, and the brain. Science 307: 375-379.
57. Sebens JB, Koch T, Ter Horst GJ, Korf J (1995). Differential Fosprotein induction in rat forebrain regions after acute and longterm haloperidol and clozapine treatment. Eur J Pharmacol 273: 175-182.
58. Seemuller F, Forsthoff A, Dittmann S, Born C, Bernhard B, Severus WE et al (2005). The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf 4: 849-868.
59. Sener A, Jijakli H, Asl SZ, Courtois P, Yates AP, Meuris S et al (2007). Possible role of carbonic anhydrase in rat pancreatic islets: enzymatic, secretory, metabolic, ionic, and electrical aspects. Am J Physiol Endocrinol Metab 292: E1624-E1630.
60. Strassnig M, Brar JS, Ganguli R (2003). Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res 62: 73-76.
61. Stratford TR, Kelley AE (1997). GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior. J Neurosci 17: 4434-4440.
62. Swanson LW (1998). Brain Maps: Structure of the Rat Brain, 2nd revised edn. Elsevier Science: BV.
63. Tandon R (2002). Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? Psychiatr Q 73: 297-311.
64. Tarricone I, Casoria M, Gozzi BF, Grieco D, Menchetti M, Serretti A et al (2006). Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC Psychiatry 6: 11.
65. Terry P, Gilbert DB, Cooper SJ (1995). Dopamine receptor subtype agonists and feeding behavior. Obes Res 3(Suppl 4): 515S-523S.
66. Tosches WA, Tisdell J (2006). Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 8: 522-526.
67. Vestri HS, Maianu L, Moellering DR, Garvey WT (2007). Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32: 765-772.
68. Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, Culver J et al (2007). Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res; e-pub ahead of print.
69. Ward HG, Nicklous DM, Aloyo VJ, Simansky KJ (2006). Mu-opioid receptor cellular function in the nucleus accumbens is essential for hedonically driven eating. Eur J Neurosci 23: 1605-1613.
70. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM (2005a). Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 288: E617-E624.
71. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM (2005b). Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 289: E1015-E1022.
72. Will MJ, Franzblau EB, Kelley AE (2003). Nucleus accumbens muopioids regulate intake of a high-fat diet via activation of a distributed brain network. J Neurosci 23: 2882-2888.
73. Wofford MR, King DS, Harrell TK (2006). Drug-induced metabolic syndrome. J Clin Hypertens (Greenwich) 8: 114-119.
74. Wroe S (2007). Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin 23: 1765-1773.